May 9, 2025 02:31 PM EDT
Pharma

Io­vance stock plum­mets af­ter low­ered full-year guid­ance, missed an­a­lyst ex­pec­ta­tions for Am­tagvi

Nicole DeFeudis

Editor

Io­vance Bio­ther­a­peu­tics’ stock $IO­VA dropped more than 44% on Fri­day af­ter­noon, a day af­ter the com­pa­ny slashed its 2025 sales pre­dic­tions and re­port­ed low­er-than-ex­pect­ed sales …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Lil­ly shuf­fles key ex­ec­u­tive po­si­tions; Mikael Dol­sten takes an­oth­er post-Pfiz­er as­sign­ment

Rev­o­lu­tion’s KRAS drugs ap­pear com­pet­i­tive in sev­er­al lung can­cer set­tings

As­traZeneca re­ports Phase 3 win for Imfinzi; Roche to build new man­u­fac­tur­ing site in Chi­na

Corvus' ear­ly-phase atopic der­mati­tis da­ta prompt stock ral­ly

Lon­za says its US-based sites are in high de­mand as phar­ma tar­iffs near

sponsored

In one of the riski­est in­dus­tries — Biotech — a sure­fire way to neu­tral­ize some of that risk emerges

A service from the Financial Times